News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
143 Results
Type
Article (1)
Company Profile (1)
Press Release (141)
Section
Business (38)
Deals (4)
Drug Development (14)
FDA (2)
News (54)
Tag
Alliances (1)
Approvals (2)
Biotechnology (1)
Clinical research (9)
Compensation (2)
C-suite (1)
Data (5)
Duchenne muscular dystrophy (9)
Earnings (20)
Events (46)
Executive appointments (1)
FDA (5)
Healthcare (8)
IPO (4)
People (24)
Phase I (8)
Phase II (9)
Phase III (1)
Preclinical (9)
Regulatory (3)
Startups (1)
Date
Last 30 days (4)
Last 365 days (32)
2025 (32)
2024 (31)
2023 (18)
2022 (19)
2021 (21)
2020 (15)
2019 (7)
Location
Asia (1)
Japan (1)
Massachusetts (49)
United States (49)
143 Results for "Dyne_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
December 8, 2025
·
1 min read
Press Releases
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
December 12, 2025
·
2 min read
Press Releases
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
December 10, 2025
·
4 min read
Press Releases
Dyne Therapeutics to Present at Upcoming Investor Conferences - November 3, 2025
November 4, 2025
·
1 min read
Press Releases
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
December 8, 2025
·
15 min read
Press Releases
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 6, 2025
·
11 min read
Press Releases
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
October 3, 2025
·
5 min read
Press Releases
Dyne Therapeutics to Present at Upcoming September 2025 Investor Conferences
August 28, 2025
·
1 min read
Press Releases
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
September 30, 2025
·
7 min read
Press Releases
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
October 6, 2025
·
11 min read
1 of 15
Next
